Cyril H. Benes - Concepedia

Author

Cyril H. Benes

Also Known As

Benes, Cyril, Benes, Cyril H., C Benes, C H Benes, C. Benes, C.H. Benes, CYRIL BENES, Cyril BENES, Cyril Benes, Cyril H Benes

688

Publications

30.6K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Center for Cancer Research Wellcome Sanger Institute Dana-Farber Cancer Institute

About

Cyril H. Benes is an author at Massachusetts General Hospital specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	59	17K
2	Natural Sciences	9	9	1.1K
3	Health Sciences	8	8	684
4	Engineering	6	6	7K
5	Biochemistry	4	4	411

Cyril H. Benes

131

Publications

30.3K

Citations

H-Index

Page 1

	Year	Citations
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells Wanjuan Yang, Jorge Soares, Patricia Greninger, Nucleic Acids Research Therapeutic Biomarker DiscoveryDrug TargetEngineeringPathologyTumor Biology	2012	4.2K
Systematic identification of genomic markers of drug sensitivity in cancer cells Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn, Nature Systematic IdentificationGenomic MarkersEngineeringTumor HeterogeneityMedicine	2012	2.5K
A Landscape of Pharmacogenomic Interactions in Cancer Francesco Iorio, Theo Knijnenburg, Daniël J. Vis, Cell Tumor BiologyOncologyTumor HeterogeneityMedicineDrug Response	2016	2.2K
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers Ryohei Katayama, Alice T. Shaw, Tahsin Khan, Science Translational Medicine	2012	1.3K
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Cancer Discovery	2016	1.1K
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility Min Yu, Aditya Bardia, Nicola Aceto, Science Breast OncologyPathologyCell CultureTumor BiologyOncology	2014	895
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor Nicholas Kwiatkowski, Tinghu Zhang, Peter B. Rahl, Nature	2014	882
Patient-derived models of acquired resistance can identify effective drug combinations for cancer Adam Crystal, Alice T. Shaw, Lecia V. Sequist, Science	2014	727
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Alexandre Puissant, Stacey M. Frumm, Gabriela Alexe, Cancer Discovery Neuro-oncologyBromodomain InhibitionNovel TherapyOncogenic AgentMycn Transcription	2013	624
Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties Michael P. Menden, Francesco Iorio, Mathew J. Garnett, PLoS ONE	2013	551

Page 1